← Back to Search

Chemotherapy

Tucatinib + Trastuzumab + Chemotherapy for Colorectal Cancer (MOUNTAINEER-03 Trial)

Paris, TX
Phase 3
Recruiting
Research Sponsored by Seagen Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
Histologically and/or cytologically confirmed adenocarcinoma of the colon or rectum which is locally advanced unresectable or metastatic
Must not have
Previous treatment with anti-HER2 therapy
Ongoing Grade 3 or higher neuropathy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 6 years
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Summary

This trial is testing to see if tucatinib in combination with other drugs is more effective than standard of care drugs at treating participants with HER2 positive colorectal cancer.

See full description
Who is the study for?
This trial is for adults with HER2 positive, RAS WT metastatic or unresectable colorectal cancer who haven't had systemic anticancer therapy in the metastatic setting. They should have measurable disease and be in good physical condition (ECOG 0-1). Prior adjuvant chemotherapy is allowed if completed over 6 months ago. Excluded are those with recent radiation, ongoing severe neuropathy, GI perforation within a year, or past anti-HER2 treatment.Check my eligibility
What is being tested?
The study compares tucatinib combined with trastuzumab and mFOLFOX6 against standard treatments for advanced colorectal cancer. Participants will randomly receive either this new combination or one of the standard options: mFOLFOX6 alone, with bevacizumab, or cetuximab. The goal is to see if tucatinib improves outcomes.See study design
What are the potential side effects?
Potential side effects include reactions related to the immune system's response to drugs like tucatinib and trastuzumab; digestive issues from chemotherapy agents; nerve damage risks from oxaliplatin; and general symptoms such as fatigue and increased risk of infections.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
 show original
Select...
My colon or rectum cancer is advanced and cannot be removed by surgery.
 show original
Select...
My cancer is HER2 positive based on a specialized lab test.
 show original
Select...
I have provided a recent biopsy of my tumor if no older samples were available.
 show original
Select...
My cancer can be measured on scans and has grown after any previous radiation.
 show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been treated with anti-HER2 therapy before.
 show original
Select...
I have severe nerve pain or damage.
 show original
Select...
I have not had radiation therapy in the last 14 days, or 7 days if it was stereotactic radiosurgery.
 show original

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 6 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 6 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Blinded Independent Central Review (BICR)
Secondary study objectives
Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQC30) score
Confirmed objective response rate (cORR) per RECIST v1.1 by BICR
DOR per RECIST v1.1 by investigator assessment
+8 more

Side effects data

From 2024 Phase 2 & 3 trial • 17 Patients • NCT04499924
50%
Diarrhoea
50%
Rash
38%
Alopecia
38%
Aspartate aminotransferase increased
38%
Constipation
38%
Pyrexia
25%
Stomatitis
25%
Weight decreased
25%
Abdominal pain
25%
Myalgia
25%
Epistaxis
25%
Hypertension
25%
Fatigue
25%
Nausea
25%
Alanine aminotransferase increased
25%
Anaemia
25%
Ejection fraction decreased
25%
Dermatitis acneiform
13%
Gastritis
13%
Dizziness
13%
Anal haemorrhage
13%
Rectal abscess
13%
Neck pain
13%
Cough
13%
Dyspnoea
13%
Neutropenia
13%
Dyspepsia
13%
Vomiting
13%
Chills
13%
Localised oedema
13%
Skin infection
13%
Hyphaema
13%
Infusion related reaction
13%
Temperature intolerance
13%
Arthralgia
13%
Thrombocytopenia
13%
Eye pruritus
13%
Fall
13%
Acute kidney injury
13%
Rhinorrhoea
13%
Decreased appetite
13%
Skin laceration
13%
Myofascial pain syndrome
13%
Chromaturia
13%
Palmar-plantar erythrodysaesthesia syndrome
13%
Enteritis
13%
Respiratory failure
13%
Gastric haemorrhage
13%
Tympanic membrane perforation
13%
Anal fissure
13%
Gastrooesophageal reflux disease
13%
Haemorrhoids
13%
Odynophagia
13%
Peripheral swelling
13%
Hyperbilirubinaemia
13%
COVID-19
13%
Peripheral sensory neuropathy
13%
Hypotension
13%
Intestinal sepsis
13%
Pneumonia
13%
Pneumothorax
13%
Night sweats
13%
Pruritus
100%
80%
60%
40%
20%
0%
Study treatment Arm
Paclitaxel 60 mg/m^2
Paclitaxel 80 mg/m^2

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Tucatinib ArmExperimental Treatment6 Interventions
Tucatinib + trastuzumab + mFOLFOX6
Group II: Standard of Care ArmActive Control6 Interventions
mFOLFOX6 + (bevacizumab OR cetuximab). Either (1) mFOLFOX6, (2) mFOLFOX6 and bevacizumab, or (3) mFOLFOX6 and cetuximab
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
tucatinib
2021
Completed Phase 3
~810
trastuzumab
2002
Completed Phase 3
~1790
oxaliplatin
2002
Completed Phase 3
~6370
leucovorin
2005
Completed Phase 3
~1260
fluorouracil
1994
Completed Phase 3
~8440

Find a Location

Closest Location:Baptist Health Lexington· Lexington, KY· 159 miles

Who is running the clinical trial?

Seagen Inc.Lead Sponsor
211 Previous Clinical Trials
73,270 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
4,085 Previous Clinical Trials
5,223,479 Total Patients Enrolled
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,583 Previous Clinical Trials
47,965,278 Total Patients Enrolled
James Ward, MDStudy DirectorSeagen Inc.
Jorge Ramos, DOStudy DirectorSeagen Inc.
4 Previous Clinical Trials
1,016 Total Patients Enrolled
Medical MonitorStudy DirectorSeagen Inc.
1,679 Previous Clinical Trials
988,514 Total Patients Enrolled

Media Library

Fluorouracil (Chemotherapy) Clinical Trial Eligibility Overview. Trial Name: NCT05253651 — Phase 3
Colorectal Cancer Research Study Groups: Tucatinib Arm, Standard of Care Arm
Colorectal Cancer Clinical Trial 2023: Fluorouracil Highlights & Side Effects. Trial Name: NCT05253651 — Phase 3
Fluorouracil (Chemotherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05253651 — Phase 3
~117 spots leftby Apr 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top